ECSP003483A - NEW PHARMACEUTICAL COMBINATIONS FOR HOS INHIBITORS - Google Patents
NEW PHARMACEUTICAL COMBINATIONS FOR HOS INHIBITORSInfo
- Publication number
- ECSP003483A ECSP003483A ECSP003483A ECSP003483A EC SP003483 A ECSP003483 A EC SP003483A EC SP003483 A ECSP003483 A EC SP003483A EC SP003483 A ECSP003483 A EC SP003483A
- Authority
- EC
- Ecuador
- Prior art keywords
- disorders
- sleep
- inhibitors
- disorder
- nos
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 3
- 208000019116 sleep disease Diseases 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 201000004569 Blindness Diseases 0.000 abstract 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 abstract 1
- 208000008967 Enuresis Diseases 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 abstract 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000006199 Parasomnias Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 208000010340 Sleep Deprivation Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000002060 circadian Effects 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010020765 hypersomnia Diseases 0.000 abstract 1
- 230000001788 irregular Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 208000005346 nocturnal enuresis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- 208000012672 seasonal affective disease Diseases 0.000 abstract 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos usos farmacéuticos para compuestos que presentan actividad como inhibidores de la oxido nitrico sintasa (NOS). Específicamente, se refiere al uso de inhibidores de la NOS, particularmente de inhibidores selectivos de la NOS neuronal (nNOS), solos o en combinación con otros agente activo, en particular, en SSRI o un antagonista del receptor NK-1, para el tratamiento de transtornos o afecciones cuyo tratamiento puede realizrse o facilitarse mediante la alteración de los ritmos circadianos. Son ejemplos de tales transtornos y afecciones la ceguera, la obesidad, el transtorno afectivo estacional, el transtorno bipolar, el desfase horario, transtorno de los ritmos circadianos del sueño, privación de sueño, parasomnias, transtornos del sueño REM, hipersomnia, trastornos de los ciclos de suefio-vigila, narcolepsia y trastornos del sueño asociados con el trabajo a turnos con horarios de trabajo irregulares; enuresis nocturna y síndrome de las piernas inquietas.The present invention relates to new pharmaceutical uses for compounds that exhibit activity as inhibitors of nitric oxide synthase (NOS). Specifically, it refers to the use of NOS inhibitors, particularly selective neuronal NOS inhibitors (nNOS), alone or in combination with other active agents, in particular, in SSRI or an NK-1 receptor antagonist, for treatment of disorders or conditions whose treatment can be performed or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, time lag, disorder of circadian sleep rhythms, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, disorders of the cycles of sleep-monitoring, narcolepsy and sleep disorders associated with shift work with irregular work schedules; nocturnal enuresis and restless legs syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003483 ECSP003483A (en) | 2000-05-19 | 2000-05-19 | NEW PHARMACEUTICAL COMBINATIONS FOR HOS INHIBITORS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003483 ECSP003483A (en) | 2000-05-19 | 2000-05-19 | NEW PHARMACEUTICAL COMBINATIONS FOR HOS INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003483A true ECSP003483A (en) | 2001-12-28 |
Family
ID=42041109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003483 ECSP003483A (en) | 2000-05-19 | 2000-05-19 | NEW PHARMACEUTICAL COMBINATIONS FOR HOS INHIBITORS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003483A (en) |
-
2000
- 2000-05-19 EC ECSP003483 patent/ECSP003483A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR022640A1 (en) | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | |
| PE20221730A1 (en) | CYCLOALKYLUREA DERIVATIVE | |
| UY28239A1 (en) | BENCENOSULFONAMIDE DERIVATIVES | |
| AR043356A1 (en) | SUSTAINED RELEASE DEVICE FOR THE OCULAR ADMINISTRATION OF CARBON ANHYDRATION INHIBITORS AND USE OF CARBON ANHYDRATION INHIBITORS FOR PREPARATION | |
| AR080143A1 (en) | PIRROLIDINA-2-SUBSTITUTED CARBOXAMIDS, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE TREATMENT OF ONCOLOGICAL DISORDERS | |
| HN2000000020A (en) | INHIBITORS OF THE RECOVERY OF MONOAMINS FOR THE TREATMENT OF CNS DISORDERS. | |
| PE20191496A1 (en) | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | |
| MX2015012760A (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof. | |
| CR10166A (en) | USE OF BENZO-FUSION HETEROCICLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF BIPOLAR DISORDER AND MANIA | |
| PE20150709A1 (en) | BENZAMIDES | |
| MX2021005839A (en) | ANTAGONISTS OF THE ADENOSINE AMINOTRIAZOLOPYRIMIDINE AND AMINOTRIAZOLOPYRAMIDINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE. | |
| CL2012002540A1 (en) | Agomelatine Hydrochloride Hydrate; crystalline form; Preparation method; pharmaceutical composition; and its use for the treatment of sleep disorders, stress, anxiety, major depression, cardiovascular diseases, among others. | |
| CR8928A (en) | ARILSULPHONYLESTILBEN DERIVATIVES FOR INSOMNIA TREATMENT AND RELATED AFFECTIONS | |
| CL2012003637A1 (en) | Compounds derived from substituted quinazoline or triazolopyridine, selective tyrosine kinase inhibitors; medicine; pharmaceutical composition; and its use to treat, prevent or improve retinal / macular edema, age-related macular degeneration and retinal vascular effusion related to ischemia, among others. | |
| CL2011002792A1 (en) | Compounds derived from methoxyphenyl furan-3- (2h) -one, phosphodiesterase 10 (pde10) inhibitors; pharmaceutical composition comprising one of the compounds; and use of the pharmaceutical composition in the preparation of drugs to treat eating disorders, obesity, compulsive gambling, narcolepsy, among others. | |
| MX2014012742A (en) | COMPOSITION FOR THE TREATMENT OF METABOLIC DISORDERS. | |
| CL2021003032A1 (en) | Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor. | |
| CL2009000876A1 (en) | Crystalline form anhydrous orvepitant maleate; pharmaceutical composition; and its use to treat disorders of the central nervous system, such as depression, anxiety, post-traumatic stress disorders, emesis, and / or sleep disorders. | |
| Vučković et al. | Synergistic interaction between ketamine and magnesium in lowering body temperature in rats | |
| EA201690179A1 (en) | V1A RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS ASSOCIATED WITH SHEEP PHASE SHIFT | |
| ECSP003483A (en) | NEW PHARMACEUTICAL COMBINATIONS FOR HOS INHIBITORS | |
| UY27177A1 (en) | NEW HETEROCYCLIC DERIVATIVES OF UREA AND ITS USES AS LINKS TO DOPAMINE D3 RECEIVER. | |
| ECSP15025868A (en) | COMPOSITION INCLUDING AN ISOLATED PURIFIED EXTRACT OF PSEUDOLYSIMACHION ROTUNDUM VAR. SUBINTEGRUM CONTAINING AN ABUNDANT QUANTITY OF ACTIVE INGREDIENT OR THE ISOLATED COMPOUNDS THEREOF, AS AN ACTIVE INGREDIENT TO PREVENT / TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND ITS USE | |
| MY180772A (en) | Novel therapeutic mirtazapine combinations for use in pain disorders | |
| PA8479801A1 (en) | NEW PHARMACEUTICAL USES FOR US INHIBITORS |